chufangao/CTO huggingface dataset:
Clinical trial NCT04270929: Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Official title: Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Acronym: PANC-001
Sponsor: Roger Williams Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Insufficient accrual rate
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-23
Primary completion date: 2021-05-04
Completion date: 2021-05-04
Plan to share individual participant data: NO
Clinical trial NCT04648319: A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma
Official title: A Pilot Study of BMS-936558 With Stereotactic Ablative Radiation Therapy After Induction Chemotherapy in Cholangiocarcinoma
Sponsor: American University of Beirut Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: pharma company decision to withdraw the financial and IMP support
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-15
Primary completion date: 2022-01-17
Completion date: 2022-01-17
Plan to share individual participant data: NO
Clinical trial NCT05162066: Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Official title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
Acronym: RENEW
Sponsor: BioCryst Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-02-18
Primary completion date: 2022-09-23
Completion date: 2022-09-23
Baseline population: Safety population included all participants who received at least one dose of the study drug.
Limitations and caveats: The sponsor decided to prematurely terminate the study due to changes in the competitive landscape. Due to low enrolment in the study (N=2) and early termination of both participants, very limited data were available for analyses. Therefore, only key efficacy endpoints (24-hour uPCR, 24-hour urine protein excretion, and eGFR) and safety were analyzed and reported.
Plan to share individual participant data: NO
Clinical trial NCT04242368: Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis
Official title: Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: COVID-19 pandemic, unable to recruit and conduct study procedures per state, local, and university policies.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-01
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Plan to share individual participant data: NO
Clinical trial NCT04133480: Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
Official title: An Open-Label Exploratory Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (EPIDIOLEX®; GWP42003-P)
Acronym: EPI-COG
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase IV study requiring multiple clinic visits when medication is commercially available. The study was withdrawn before any participants were recruited.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04509466: Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
Official title: A Multicentre, Open-label, Single-arm, Phase I/II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The sponsor has adjusted its R\&D strategy.
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-15
Primary completion date: 2022-01-30
Completion date: 2022-01-30
Plan to share individual participant data: NO
Clinical trial NCT04186156: A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
Official title: A Phase II Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer Previously Treated With Standard of Care Chemotherapy (ABC-11)
Sponsor: Karus Therapeutics Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study not progressing
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-05
Primary completion date: 2023-03-31
Completion date: 2023-10-31
Plan to share individual participant data: NO
Clinical trial NCT05010096: BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
Official title: Strategic Alliance: Phase 1b Trial of the Combination of the ATR Inhibitor BAY1895344 and PI3K Inhibitor Copanlisib in Molecularly Selected Patients With Advanced Solid Tumors (COPABAY)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-22
Primary completion date: 2022-03-22
Completion date: 2022-03-22
Clinical trial NCT04346329: Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19
Official title: Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2
Acronym: Chloroquine UN
Sponsor: Universidad Nacional de Colombia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study did not get financed. Never got started.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-30
Primary completion date: 2020-06-30
Completion date: 2020-10-30
Plan to share individual participant data: NO
Clinical trial NCT04388683: Inhaled Nitric Oxide for Preventing Progression in COVID-19
Official title: Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.
Acronym: NO-COVID-19
Sponsor: Tufts Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Bellerophon requested study to be stopped.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-12
Primary completion date: 2020-11-23
Completion date: 2020-11-23
Limitations and caveats: The study was terminated early by request of the company providing the iNO Drug. Our data set is small are analysis was effected by this.
Plan to share individual participant data: NO
IPD sharing description: Data from this pilot study will be used to plan future a larger randomized controlled outcome trial.
Clinical trial NCT04971005: Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
Official title: A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)
Acronym: COAST
Sponsor: Universitätsklinikum Hamburg-Eppendorf (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of recruitment due to low acceptance of the control arm.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-27
Primary completion date: 2022-02-04
Completion date: 2022-02-04
Clinical trial NCT03400852: A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy
Official title: A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy
Acronym: BRAVE
Sponsor: Mallinckrodt (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 44.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-27
Primary completion date: 2020-02-25
Completion date: 2020-02-25
Baseline population: All participants enrolled into the study.
Plan to share individual participant data: NO
IPD sharing description: Discussion of statistical endpoints and analysis are included in manuscripts. Summary aggregate (basic) results (including adverse events information) and the study protocol are made available on clinicaltrials.gov (NCT03400852) when required by regulation. Individual de-identified patient data will not be disclosed. Requests for additional information should be directed to the company at medinfo@mnk.com.
Clinical trial NCT03810183: A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
Official title: A Multi-center, Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company decision
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-21
Primary completion date: 2020-01-16
Completion date: 2020-01-16
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT05107115: Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment
Acronym: RILECSU
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 161.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-11-24
Primary completion date: 2023-07-19
Completion date: 2024-04-23
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04552704: CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
Official title: Treatment of Immune Related Adverse Events With CD24Fc (TIRAEC)
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated early by the Sponsor due to business reason.
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-10-30
Primary completion date: 2021-02-03
Completion date: 2022-01-26
Baseline population: The study was terminated by the sponsor after 3 out of 6 patients enrolled in phase I study.
Limitations and caveats: The study was terminated by the sponsor after 3 out of 6 patients enrolled in phase I study.
Clinical trial NCT04055883: Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD
Official title: A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease
Acronym: DIP-CAVD
Sponsor: Dong-A ST Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 228.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-08-26
Primary completion date: 2023-02-01
Completion date: 2023-02-01
Clinical trial NCT02792231: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Official title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Acronym: ASCLEPIOS II
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 955.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-26
Primary completion date: 2019-07-10
Completion date: 2020-10-22
Baseline population: It was pre-specified in the protocol to combine the data from this study with study NCT02792218 (COMB157G2301) for some outcome measures. Please refer to NCT02792218 for Baseline information for participants from other study.
Limitations and caveats: This study was not powered for the analysis of some secondary endpoints as a stand-alone study. It was pre-specified in the study protocol to combine the data with study COMB157G2301 to address these endpoints.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT05268926: TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension
Official title: TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension
Acronym: TIMOTHY
Sponsor: University Medical Center Groningen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to a delayed start-up and delayed patient inclusion in combination with new available scientific data, continuation of the clinical study no longer serves a scientific purpose.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-03
Primary completion date: 2023-02-02
Completion date: 2023-02-02
Clinical trial NCT03754244: A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
Official title: A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The enrolment task cannot be gotten within the planned time.It mainly includes patients with non-small cell lung cancer failed in standard treatment,with a short survival period.It is hard to obtain observational endpoints for bone-related events.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-24
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Plan to share individual participant data: NO
Clinical trial NCT02721069: Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects
Official title: A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)
Sponsor: Neurelis, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 175.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-11
Primary completion date: 2020-06-17
Completion date: 2020-07-23
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01715285: A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Official title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1209.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-02-12
Primary completion date: 2016-10-31
Completion date: 2022-02-13
Baseline population: Intent-to-Treat (ITT) analysis set included all participants randomized into the study and who were classified according to their assigned treatment group, regardless of the actual treatment received. .
Limitations and caveats: As per protocol the long-term extension (LTE) phase was planned but LTE phase is not included as part of this study hence no data was reported for LTE phase.
Clinical trial NCT03104725: Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
Official title: Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Difficulty with recruitment and participant accrual due to study eligibility criteria and required study procedures (e.g., multiple lumbar punctures).
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-25
Primary completion date: 2020-02-27
Completion date: 2020-02-27
Clinical trial NCT04738981: Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT
Official title: Efficacy and Safety of UC-MSCS for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT: A Multicenter, Randomized, Open-label Trial
Sponsor: Peking University People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 130.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2022-05-30
Completion date: 2023-05-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04941989: A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562
Official title: A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Subcutaneous HTL0022562 in Healthy Adult Subjects
Sponsor: Nxera Pharma UK Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Early termination of study pending evaluation of emerging preclinical profile.
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-22
Primary completion date: 2021-11-23
Completion date: 2021-11-23
Plan to share individual participant data: NO
Clinical trial NCT01725490: The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study
Sponsor: Yonsei University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 34.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-02-15
Primary completion date: 2020-08-30
Completion date: 2020-08-30
Clinical trial NCT03066154: Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
Official title: Weekly ModraDoc/r in Combination With Hormonal Treatment and High-dose Intensity-modulated Radiation Therapy in Patients With High-risk Early Stage Prostate Cancer
Acronym: DOP
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: low inclusion of patients and availability of the IP
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-30
Primary completion date: 2022-02-28
Completion date: 2022-08-31
Plan to share individual participant data: NO
Clinical trial NCT04762186: Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
Official title: A Phase I/ Randomized Phase II Trial to Analyse Safety and Efficacy of Human SARS-CoV-2-specific T Lymphocyte Transfer in Patients With COVID-19 in Need of Treatment or at Risk of Severe COVID-19
Acronym: ACT-COVID-19
Sponsor: Universitätsklinikum Köln (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: poor recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-08
Primary completion date: 2022-08-03
Completion date: 2022-08-03
Clinical trial NCT04329195: ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
Official title: ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study
Acronym: ACORES-2
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: insufficient recrutment
Enrollment: 44.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-09
Primary completion date: 2020-12-09
Completion date: 2021-01-09
Clinical trial NCT04499235: A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
Official title: Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid
Sponsor: Alkahest, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was prematurely terminated by the Sponsor due to operational challenges stemming from the coronavirus disease 2019 (COVID-19) pandemic, treatment limitations, rarity of the disease, and drug supply considerations.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-30
Primary completion date: 2021-03-29
Completion date: 2021-04-14
Plan to share individual participant data: NO
Clinical trial NCT04206865: Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output
Official title: Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output
Acronym: PARAVLO-HF
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: New study initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-25
Primary completion date: 2020-09-10
Completion date: 2020-09-10
Clinical trial NCT04390243: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
Official title: BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-16
Primary completion date: 2023-11-01
Completion date: 2023-11-01